Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Buy at StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Tuesday.

Several other research analysts have also recently weighed in on the stock. HC Wainwright upgraded shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Tuesday, July 30th. Truist Financial lifted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $37.00 price target (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and lifted their price objective for the company from $41.00 to $44.00 in a research report on Friday, June 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $35.62 on Tuesday. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14. Collegium Pharmaceutical has a 1 year low of $20.95 and a 1 year high of $40.95. The company has a market cap of $1.17 billion, a P/E ratio of 14.84 and a beta of 0.93. The stock’s fifty day moving average price is $33.65 and its 200-day moving average price is $34.97.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The business had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. During the same period in the previous year, the company posted $1.13 EPS. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, equities analysts forecast that Collegium Pharmaceutical will post 5.73 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the transaction, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the sale, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. lifted its stake in shares of Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after purchasing an additional 821,541 shares during the last quarter. Rubric Capital Management LP boosted its position in Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares in the last quarter. Vanguard Group Inc. boosted its stake in Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after acquiring an additional 17,942 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Collegium Pharmaceutical by 8.2% during the second quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock worth $54,124,000 after acquiring an additional 128,003 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Collegium Pharmaceutical by 8.0% in the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.